Enterprise Therapeutics raises 29 mln pounds
Enterprise Therapeutics Ltd said April 12 that it raised 29 million pounds ($41 million) in a Series B round co-led by Versant Ventures and Novartis Venture Fund. The syndicate also included new investor Forbion, founding investor Epidarex Capital and existing investor IP Group. Enterprise Therapeutics Ltd is a biopharmaceutical company that is developing therapies for the treatment of respiratory diseases.
12 April 2018•3 mins read
